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Abstract
Background: trials to identify the minimal eﬀective treatment duration are needed in diﬀerent therapeutic
areas, including bacterial infections, TB and HepatitisC. However, standard non-inferiority designs have several
limitations, including arbitrariness of non-inferiority margins, choice of research arms and very large sample sizes.
Methods: we recast the problem of ﬁnding an appropriate non-inferior treatment duration in terms of modelling
the entire duration-response curve within a pre-speciﬁed range. We propose a multi-arm randomised trial design,
allocating patients to diﬀerent treatment durations. We use fractional polynomials and spline-based methods to
ﬂexibly model the duration-response curve. We call this a Durations design. We compare diﬀerent methods in
terms of a scaled version of the area between true and estimated prediction curves. We evaluate sensitivity to key
design parameters, including sample size, number and position of arms.
Results: a total sample size of ∼ 500 patients divided into a moderate number of equidistant arms (5-7) is
suﬃcient to estimate the duration-response curve within a 5% error margin in 95% of the simulations. Fractional
polynomials provide similar or better results than spline-based methods in most scenarios.
Conclusions: our proposed practical randomised trial Durations design shows promising performance in the
estimation of the duration-response curve; subject to a pending careful investigation of its inferential properties,
it provides a potential alternative to standard non-inferiority designs, avoiding many of their limitations, and yet
being fairly robust to diﬀerent possible duration-response curves. The trial outcome is the whole duration-response
curve, which may be used by clinicians and policy makers to make informed decisions, facilitating a move away
from a forced binary hypothesis testing paradigm.
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Introduction
While much early phase drug development focusses on identifying the most appropriate dose, for many
conditions less emphasis is placed on identifying the most appropriate treatment duration. Consequently,
duration is often based as much on precedent as evidence. A motivating example is bacterial infections,
where concerns about under-treatment and low costs have historically led to long antibiotic courses. However,
widespread antibiotic overuse over the last decades, for example for non-bacterial infections or for longer than
necessary to cure an infection, is now considered the main driver for increasing antimicrobial resistance [1,2].
How to design trials to optimise treatment duration (which will often take the form of ﬁnding the shortest
eﬀective treatment duration) is, however, unclear.
The most widely used design is a non-inferiority trial [3,4]; two key design choices are the new duration of
therapy and the non-inferiority margin, i.e. the maximum diﬀerence in eﬃcacy of the new versus standard
treatment duration that investigators will tolerate. If the whole conﬁdence interval (CI) for the diﬀerence in
treatment eﬃcacy lies below this margin, non-inferiority of the shorter duration is demonstrated. However,
non-inferiority trials have been often criticized [5]; key limitations are:
• The non-inferiority margin is somewhat arbitrary, typically being a multiple of 5% on the absolute
diﬀerence scale. European Medicines Agency guidance [6] recommends that the non-inferiority margin
for antibiotic trials should be decided so that equivalent eﬃcacy versus placebo can be excluded, e.g.
if cure rates are 80% with control and 20% without antibiotics, then the non-inferiority margin should
ensure that the intervention has ≥ 20% cure rate. This is rarely helpful, given low cure rates for
serious infections without antibiotics, and high cure rates with antibiotics (also see Food and Drug
Administration Guidance [7]). Furthermore, at the design stage, there is often relatively little a-priori
information on the expected control event rate [8] and variation even between 80− 90% can substantially
impact the sample size required to demonstrate non-inferiority on an absolute scale;
• Whether the CI should be 95% (two-sided alpha=0.05, one-sided alpha=0.025) or 90% (two-sided
alpha=0.10, one-sided alpha=0.05) is still debated;
• Consequently, sample sizes for non-inferiority trials with reasonably small margins (5%) are usually
very large, and they are often unsuccessful [9];
• The shorter duration(s) to be tested have to be chosen in advance; again, limited prior knowledge
makes this choice diﬃcult. A bad choice inevitably leads to failure of the trial or an unnecessarily
long duration being adopted in clinical practice. Comparing multiple durations increases the chance of
selecting sensible durations to test, but requires even bigger sample sizes with the traditional design;
• There is no consensus for best analysis methods for non-inferiority trials; both intention-to-treat and
per-protocol approach can lead to unreliable results. International recommendations diﬀer [5]; at best,
leading to challenges in interpretation and, at worst, to manipulation towards the most favourable
results.
An alternative approach to non-inferiority trials is therefore attractive, but relatively little work has been
done in this area. A recent proposal is the DOOR/RADAR trial design [10]. Response Adjusted for Duration
of Antibiotic Risk (RADAR) ﬁrst categorises patients using a composite clinical outcome (based on beneﬁts
and harms), and then successively ranks them with respect to a Desirability Of Outcome Ranking (DOOR),
assigning higher ranks to patients with better composite outcomes and shorter antibiotic durations. Finally
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the probability that a randomly selected patient will have a better DOOR if assigned to the new treatment
duration is calculated. The main criticisms of DOOR/RADAR are that combining clinical outcome and
treatment duration into a single composite may hide important diﬀerences in the clinical outcome alone and
intrinsically assumes (rather than estimates) that shorter durations are beneﬁcial, and hence the clinical
interpretation of the treatment eﬀect on the composite endpoint is far from clear. Phillips et al. [11] showed
that two non-inferiority trials where shorter durations had been unequivocally demonstrated not to be non-
inferior would have instead demonstrated non-inferiority using DOOR/RADAR.
To identify appropriate treatment durations, another possible approach is to model the duration-response
curve, borrowing information from other durations when calculating treatment eﬀect at a particular duration.
This was ﬁrst proposed, in a limited way, by Horsburgh et al. [12] where, on the log-odds scale, the eﬀect of
duration on response rate was assumed to be linear (logistic regression model).
However, in general, and certainly for antibiotic treatment duration, this strong assumption is unlikely to
hold. Therefore, here we instead propose using ﬂexible regression modelling strategies to model the duration-
response curve, to provide robustness under general forms of the true duration-response curve.
Proposals
Suppose a treatment T has currently recommended duration Dmax and there is a minimum duration Dmin
we are willing to compare with Dmax, possibly because an even shorter duration is thought unlikely to be
suﬃciently eﬀective. Our goal is to model the duration-response curve for response Y between Dmin and
Dmax. In the equations below, Y can be either a continuous outcome or a linear predictor of a binary outcome
(representing cure). In simulations, we will assume Dmin = 10 and Dmax = 20.
The most appropriate design depends on the true shape of the duration-response curve; we therefore have
to ensure robustness against a series of diﬀerent scenarios. For example, allocating patients to only two arms,
at Dmax and Dmin would be a very good design if the duration-response curve was linear, but a terrible
design for quadratic duration-response relationships.
Therefore, instead of focusing on a single duration-response curve, we simulated data from a set of plausible
duration-response curves, and then evaluated several study designs across these scenarios. In particular we
explored the eﬀect of changing: (i) total sample size N , (ii) number and (iii) position of duration arms and
(iv) the type of ﬂexible regression model used.
However, to select the most accurate procedure for estimating the duration-response curve, we need to
choose a measure of discrepancy between the true and estimated curves.
Lack of accuracy is often evaluated through either the integral error or the expected error. For a ﬁxed set
of chosen durations D = (D1, . . . , Dn) = (Dmin, . . . , Dmax), the expected error is deﬁned as:
EE =
1
n
n∑
i=1
∆(f(Di), fˆ(Di)) (1)
where ∆ represents a sensible measure of distance, e.g. squared diﬀerence or absolute diﬀerence, f(Di)
represents the true response (typically probability of cure) corresponding to treatment duration Di and
fˆ(Di) represents the corresponding estimate from the ﬁtted model. However, this sum is over the durations
deﬁning the support, e.g. only over the speciﬁed durations, while we would like to evaluate the ﬁt of the
model across the whole duration range [Dmin, Dmax]. Therefore, we instead used a type of integral error, i.e.
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a measure of accuracy deﬁned though an integral, instead of a sum, to characterize model accuracy over the
entire domain of interest D = [Dmin, Dmax]:
IE =
∫ Dmax
Dmin
∆(f(D), fˆ(D))dD (2)
We chose the absolute diﬀerence as measure of distance ∆, as it has the most straightforward interpretation,
namely the area between the true and estimated duration-response curve. Henceforth, we refer to this measure
as the Area Between Curves. However, this has as units probability-days which is challenging to interpret.
Therefore, we divided it by (Dmax −Dmin) to produce a measure on the probability scale, the scaled Area
Between Curves. For a particular ﬁtted curve, this can be interpreted as the average absolute error in the
estimation of probability of cure, with respect to a uniform distribution for duration on (Dmin, Dmax). In
some areas of the curve the model may ﬁt better, and in some others it may ﬁt worse; however this measure
provides an average across the whole duration range. We then additionally considered the maximum absolute
error in (Dmin, Dmax) and the coverage level, deﬁned as the proportion of the true curve included within
the point-wise 95% conﬁdence region around the estimated curve.
All these measures can only be calculated when the true underlying curve is known. They are therefore
only useful for simulations to evaluate the behaviour of our proposed method.
To model the duration-response curve as ﬂexibly as possible, we compared four diﬀerent regression
strategies:
1. Fractional Polynomials (FP) [13,14] of the form:
Y = β1D
p1 + . . .+ βMD
pM . (3)
with powers p1, . . . , pM taken from a special set S = {−2,−1,−0.5, 0, 0.5, 1, 2, 3}. Usually M < 3 is
suﬃcient for a good ﬁt; here, we ﬁx M = 2, producing 36 possible combinations;
2. Linear splines, with the simplest form, under a single knot K:
Y = β0 + β1D + β2(D −K)+ (4)
where (D −K)+ = 0 if D < K. We investigated linear splines with diﬀerent numbers of knots; we
present results with 3 or 5 knots. Knots are equidistant, within the duration range considered, e.g. for
3 knots, positioned at K = {12.5, 15, 17.5};
3. Linear spline with non-equidistant knots: this concentrates knots for the linear splines in the ﬁrst half
of the duration range, where the duration-response relationship is most likely to be non-linear. We use
3 knots, that we arbitrarily chose to position at K = {11, 13, 15};
4. Multivariate Adaptive Regression Splines (MARS) [15,16], which builds models of the form:
Y =
k∑
i=1
βiBi(D) (5)
where each Bi(D) can be (i) a constant, (ii) a hinge function, i.e. max(0, D −K) or max(0,K −D),
or (iii) a product of two hinge functions. A forward selection step, building on a greedy algorithm, is
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followed by a backward elimination step, to avoid over-ﬁtting. Candidate knots K are all durations
observed in the sample, i.e. all selected duration arms.
We did not consider restricted cubic splines [17] because preliminary work showed similar results to piece-
wise linear splines; therefore we focussed on linear splines for simplicity. Other non-linear regression methods
include logistic or Gompertz growth models; however, these lose ﬂexibility.
Other key design parameters are: how many diﬀerent duration arms should we allocate patients to? How
should we space arms across our duration range? How many patients should we enrol?
We addressed these questions in an extensive simulation study.
Results
The eight diﬀerent scenarios considered represented a wide range of possible duration-response relationships,
from linear to quadratic, sigmoid curves and piecewise functions (Table 1). We simulated binary responses,
representing cure of infection, from a binomial distribution with duration-speciﬁc event rates, with 1000
simulated trials for each combination of design parameters.
Base-case design. We ﬁrst ﬁxed a sample size of 504 individuals randomised between 7 equidistant duration
arms:
D = {10, 11.6, 13.3, 15, 16.6, 18.3, 20}
We kept durations unrounded, simulating a situation where an antibiotic is administered 3 times a day, and
therefore 11.6 means three times daily for eleven days and then twice on the last day. Simulated data were
analysed with a fractional polynomial logistic regression model, i.e. on the log-odds scale.
In all 8 scenarios, the worst ﬁt still led to a scaled Area Between Curves below 5.3% in 95% of simulations
(Table 2), that is, in each scenario 95% of the simulated trials led to an estimated duration-response curve
whose error in the estimation of the probability of cure was under 5.3%.
Scenarios 1, 2 and 3 had the poorest performance. Figure 1 shows the ﬁtted prediction curves for a random
sample of 100 simulations (red) against the true data generating curve (black). In Scenario 1, fractional
polynomials had diﬃculty in capturing satisfactorily the substantial change in curvature around day 12 and
14, tending to underestimate curvature at these time-points.
Best performances were obtained with Scenario 5, where the true duration-response curve is linear on the
log-odds scale, which is exactly a FP model, with a single parameter for the term with power p = 1. Similar
results were obtained for Scenario 7.
The maximum scaled Area Between Curves was smaller than 10% in all scenarios, meaning that even the
simulation leading to the worst ﬁtted prediction curve led to a total bias under 10% in all scenarios.
The median of the maximum absolute error was 5.5% across all simulations, and < 7% except for Scenario
1, meaning that, irrespective of the real data-generating mechanism, in half of the simulations even the
single design point corresponding to the worse ﬁt had an absolute error below 5.5%. When considering the
95th percentile of the same measure, this was just below 13% overall. Figure 5 (Additional material) shows
that durations corresponding to the worst absolute error tended to be in the ﬁrst part of the curves, where
treatment was less eﬀective.
Mean coverage was 95% only for Scenario 5, where the analysis model was correctly speciﬁed; however
most scenarios had coverage greater than 80% and Figure 6 (Additional Material) shows that even the 100
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simulations leading to the worst coverages approximated the true duration-response curve quite well for a
wide variety of scenarios, similarly to the randomly selected predictions in Figure 1.
Next, we investigated the sensitivity of these results to the choice of design parameters and analysis
methods.
Diﬀerent ﬂexible regression strategies. We re-analysed the same simulated data in Table 2 using either
fractional polynomials (FP), linear spline with 3 or 5 equidistant knots, linear spline with knots concentrated
in the ﬁrst half of the curve and multivariate adaptive regression splines (MARS). Only Scenario 5 is the
true model for both data generation and analysis.
For all methods, scaled areas for the ﬁtted prediction curves were fairly similar (Figure 2, (a) and (b)).
The only method with slightly inferior performance was 5-knot linear spline. FP had the smallest mean
scaled Area Between Curves across the eight scenarios, but marginally higher variability between diﬀerent
scenarios. FP was best in terms of smallest maximum absolute error, while splines better behaved in terms
of coverage (Figure 7 Additional material).
Finally, FP had an advantage in terms of monotonicity, as shown in Figure 3, comparing prediction curves
for the simulated dataset with the worst ﬁt (largest scaled Area Between Curves), across the eight scenarios,
with FP (red) or 3-knot linear spline (blue). Spline-based methods led to undulating functions, particularly in
Scenarios 4,5,6 and 8, while FP prediction curves were smoother and, at least approximately, monotonously
increasing, the only exception being the worst ﬁt from Scenario 6. Spline based methods led to even worse
prediction curves in other scenarios, particularly with smaller sample sizes (e.g. 250 patients) and with poor
knot positioning relative to arms, e.g. two adjacent knots with no arm in between.
Total sample size. One motivation for this study was large sample sizes often required for non-inferiority
trials. We therefore investigated the sensitivity of simulation results to total sample sizes varying across
N = (252, 301, 350, 406, 455, 504, 602, 756, 1001), (each divisible by 7 (arms)).
As expected, increasing total sample size reduced the scaled Area Between Curves (second row of Figure
2). With N ≥ 350, in more than half the scenarios the 95th percentile for scaled Area Between Curves
was under 5%, and in all scenarios for N ≥ 750. Therefore, above this threshold, whatever the true data-
generating curve, in at least 95% of simulated trials we estimated a duration-response curve whose error was
lower than 5%.
Figure 2 and Table 2 suggest our base-case scenario sample size of 504 might be a reasonable compromise,
guaranteeing good estimation of the duration-response curve without requiring too many patients.
Number of duration arms. Figures 4(a)-(b) compare results from allocating the same number of patients
(∼ 504) to 3, 5, 9 or 20 arms, rather than the base-case of 7 arms.
The 3-arm design was clearly inferior and generally led to worse scaled Area Between Curves. All other
designs had similar performance, and particularly distributions from 7, 9 and 20 arms appeared virtually
identical, suggesting that, compared to a base-case of 7 duration arms, there is little gain from adding
additional arms while keeping sample size ﬁxed.
Position of arms. Finally, we investigated the sensitivity of results to the position, rather than the number,
of duration arms, by comparing:
• The standard 7 equidistant arms design;
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• A `not-equidistant' arms design, with 5 arms condensed in the ﬁrst part of the curve, i.e. A =
{10, 11, 13, 15, 20}.
As for the linear spline regression model, the motivation for this choice is that the early part of the curve is
where the linearity assumption is least likely to hold.
With fractional polynomials, results were similar with both designs (Figure 4 (c)-(d)). This is mainly
because the eight scenarios have at most modest departure from linearity in the second half of the curve.
The 3-knot spline regression performed particularly poorly with the not-equidistant design, highlighting
the issue of knot choice with spline-based methods. If knots are chosen inappropriately, e.g. two adjacent
knots with no arms in between, as here, then results may be highly variable. Whilst obvious in this case,
similar issues with inappropriate knot positioning might be less trivial to identify in other situations. In
contrast, FP regression is standardised and does not require users to make additional choices.
Extensions
Having demonstrated promising performance of our proposed method, several issues remain. The ﬁrst is
accounting for uncertainty. Point-wise conﬁdence bands around the estimated curve can be calculated from
the FP regression and were used here to estimate coverage levels. These intervals were generally quite narrow,
the mean width around the estimated cure rate ranging between 7− 10% in the base-case scenarios. However,
these do not account for model selection uncertainty [18]. Broadly, since we use the same set of data that we
want to analyse to select the ﬁnal model of interest, the usual standard error estimates from the model tend
to be too small. Therefore, a measure of precision of our estimated duration-response curve would require
methods, such as bootstrap model averaging [1921].
The second issue is how the estimated duration-response curve might be used. Possible approaches that
decision-makers could take given the estimated curve include:
1. Estimating the minimum duration that achieves a certain ﬁxed acceptable cure rate (e.g. > 80%)
analogous to a cost-eﬀectiveness acceptability curve [22], together with a conﬁdence interval. We then
would be 95% conﬁdent that the upper bound would give us a cure rate greater or equal to 80%;
2. Alternatively, if we did not know the true control success rate, estimating the duration leading to a
certain acceptable loss in eﬃciency compared to the maximum duration tested, for example 10%;
3. The information gathered from the estimated curve could also be combined with other information
about toxicity or cost in a decision analytic framework.This could be particularly appealing in the
example of Hepatitis-C, where cost is quantiﬁable, but would be more complex in the antibiotic example,
where resistance is more complex.
Discussion
We have proposed a new design for randomised trials to ﬁnd eﬀective shorter durations of treatment, for
example antibiotics, broadening a previous suggestion [12]. The underpinning concept is, instead of directly
comparing a limited and arbitrarily chosen number of particular durations, to model the whole duration-
response curve across a pre-speciﬁed range of durations, in order to maximise the information gained about
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the eﬀect of shorter or longer regimens. The resulting estimate of the dose-response curve could then be used
in a variety of clinically meaningful ways.
Because of lack of information on the true shape of this duration-response curve, we used ﬂexible modelling
strategies, to protect against parametric model misspeciﬁcation. We compared four diﬀerent strategies, three
based on splines and one on fractional polynomials, concluding that, although spline-based methods can
potentially better estimate locally the duration associated with a particular cure rate, fractional polynomials
are better at providing a reasonable curve describing the evolution of the cure rate over treatment duration.
Binder et al. [23] conducted a vast simulation study comparing fractional polynomials and spline-based
methods, broadly concluding that with large datasets the two methods lead to similar results, while in
medium-sized datasets FP outperforms spline-based methods on several criteria. They also noted that a
major advantage of FP is the simplicity of implementation in standard software packages, compared to the
absence of recommendations regarding appropriate spline based methods, matching our conclusions.
While we could have used FP with more than two polynomials, we focussed on two to reduce the number
of parameters, having only a small number of duration arms in our setting. Similarly, we focussed on the
standard set of possible powers, but higher powers could be considered, if thought likely to improve ﬁt.
FP and MARS implementation in standard software packages do not allow restriction to monotonously
increasing functions; since it is reasonable to assume monotonicity of the duration-response curve, this could
be explored in future.
Regarding design parameters, a modest number of equidistant arms, e.g. 7, appeared suﬃcient to give
robust results, i.e. the resulting prediction curve from the ﬁt of the model was reasonably close to the true
underlying duration-response curve, and can therefore provide suﬃcient information for clinicians about the
eﬀect of duration on treatment response. The `not-equidistant' design provided similar results with only 5
arms (but the same number of patients); however, such a design might be less robust to other shapes of
the duration-response curve, e.g. if the curve was far from linear even in the second part of the duration
range investigated. When multi-arm multi-stage designs were ﬁrst mooted, multiple arms were often raised
as a theoretical barrier to recruitment, but subsequent practice has demonstrated that, if anything, these
trials are more acceptable to patients, since they ably demonstrate equipoise between a substantial number
of treatment options [24].
One legitimate criticism of non-inferiority trials is the arbitrary nature of the non-inferiority margin; in our
framework, since Dmax represents the currently recommended treatment duration, the only arbitrary choice
is that of the minimum duration to be considered, Dmin. This choice certainly has a much smaller impact on
the trial results than the choice of a non-inferiority margin, but nevertheless it is still extremely important
to choose this carefully. Since we lack any information about the true shape of the duration-response curve
below the currently recommended duration, Dmax, a multi-stage adaptive design could be used to change
the position of Dmin if results after a ﬁrst stage clearly showed this to be too long (i.e. the shortest duration
still leading to high eﬃcacy) or too short (i.e. duration extremely ineﬀective, which might be considered
unethical to keep randomising patients to).
Here, we have considered models where the only covariate was treatment duration; however, it would be
interesting to investigate the eﬀect of incorporating additional covariate data, such as age and sex. This
could be done as a main eﬀect, for example to adjust the minimum duration needed to achieve a threshold
cure rate according to other characteristics aﬀecting cure; alternatively, this could be done as an interaction,
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providing a diﬀerent duration-response curve for speciﬁed subgroups, e.g. males vs females. Either would
allow stratiﬁed or personalised medicine, allowing clinicians to prescribe diﬀerent durations according to key
patient characteristics.
The underpinning motivation for this paper was a phase-IV trial design to identify minimal eﬀective
antibiotic treatment duration, and the design could be applied to other similar situations. However, an
evaluation of the inferential properties of the methodology is key before recommending it in these late phase
settings; in particular, preservation of type-I error rate is fundamental, as these are treatments that are known
to be eﬀective, and recommending an insuﬃciently long duration could potentially have serious public health
consequences. Once this is done, examples of applications may include phase-III trials in TB, where shorter
treatment durations could improve adherence compared to standard-of-care control duration, or phase-IV
trials in Hepatitis-C where current treatment regimens achieve cure in > 95% of patients but are extremely
costly. Similar approaches could be applied to dose-intensity of chemotherapy regimens.
The problem addressed here has similarities with that of ﬁnding the optimal treatment dose in early-phase
clinical trials. There is a vast literature on methods for modelling dose-response relationship to ﬁnd optimal
treatment doses [25,26]. However, there are important diﬀerences making it diﬃcult to use those methods
in our situation. The sample sizes required are much smaller in dose-response studies, because the guiding
principle is to start with a low dose and to increase it, avoiding exposing too many patients to excessive,
and thus unsafe, doses. This is usually done before the drug has actually been tested in phase II-III trials.
The power of these methods to identify the correct minimum eﬀective dose is therefore often quite low [27].
With larger sample sizes, methods like the Continual Reassessment Method become infeasible, most of all in
the example of TB where treatment may last several months. Furthermore, in early-stage trials, the focus is
often on pharmacokinetics, and the speciﬁc forms of the dose-response curves used usually derive from the
underlying pharmacokinetic models for drug absorption into the bloodstream.
In conclusion, our proposed new paradigm for clinical trials to optimise treatment duration has the
potential to revolutionise the design of trials where reducing treatment duration is our goal, e.g. in the
ﬁght against anti-microbial resistance. Our approach moves away from multiple ineﬃcient trials of arbitrary
antibiotic durations that may all be suboptimal. We have shown how certain design parameters may aﬀect
the ﬁt of a ﬂexible regression strategy to model the duration-response curve. Randomising approximately
500 patients between a moderate number of equidistant arms (5-7) is suﬃcient under a range of diﬀerent
possible scenarios to give a good ﬁt and describe the duration-response curve well. Further work on how to
use this estimated curve to draw inference, controlling power and type-I error rate, will follow.
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Type Equation Characteristics Plot
1. Logistic growth
curve
Psuccess =
0.05 +
0.9
1 + exp(−2D + 25)
Increases and asymptotes
early
2. Gompertz curve A
Psuccess =
0.9 exp(− exp(−0.5(D − 11))) Small curvature
3. Gompertz curve B
Psuccess =
0.9 exp(− exp(−(D − 11)))
Larger curvature, asymptotes
more clearly
4. Gompertz curve C
Psuccess =
0.9 exp(−2 exp(−(D − 9))) Asymptotes extremely early
5. Linear
duration-response
curve on logodds scale
logit(Psuccess) =
0.847 + 0.210(D − 10)
Situation where simple logistic
regression is appropriate
6. Quadratic
duration-response
curve, curvature>0
Psuccess =
0.7 + 0.0015(D − 10)2 First derivative increasing
7. Quadratic
duration-response
curve, curvature<0
Psuccess = 0.7− 0.0015(D −
10)2 + 0.03(D − 10) First derivative decreasing
8. Piece-wise linear
duration-response
curve
Psuccess=
(0.5 + 0.15(D − 10))1(D <
12) + (0.8 + 0.05(D −
12))1(D < 15) + (0.94 +
0.01(D − 15))1(D > 15)
Diﬀerent from linear spline
logistic regression, here it is
linear in the success rate, not
in the logodds
Table 1. Simulation scenarios: eight diﬀerent data generating mechanisms were investigated. In plots, x axis is treatment
duration, and y axis is probability of cure.
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sABC maxd AE(d) Coverage (%)
Min 5th percentile Med. 95th percentile Max Med. 95th percentile Mean
Scenario 1 0.019 0.022 0.032 0.051 0.077 0.105 0.164 61.0
Scenario 2 0.005 0.006 0.024 0.053 0.082 0.047 0.128 83.4
Scenario 3 0.003 0.007 0.022 0.048 0.079 0.055 0.123 86.8
Scenario 4 0.007 0.010 0.022 0.039 0.050 0.066 0.105 79.6
Scenario 5 0.000∗ 0.003∗ 0.015∗ 0.030∗ 0.061∗ 0.030∗ 0.078∗ 94.7∗
Scenario 6 0.011 0.012 0.022 0.044 0.066 0.051 0.100 89.5
Scenario 7 0.002 0.004 0.015 0.031 0.056 0.033 0.082 92.9
Scenario 8 0.009 0.010 0.025 0.041 0.061 0.070 0.138 72.7
Overall 0.000 0.006 0.022 0.046 0.082 0.055 0.129 82.6
Table 2. Scaled Area Between Curves (sABC), maxdAE(d) and coverage (%) across the 8 diﬀerent scenarios in the
base-case design (1000 simulations of 504 patients randomised across 7 arms, using FP). Column for the 95th scaled Area
Between Curves is in bold, to show how scaled Area Between Curves is smaller, or close to, 5% in all scenarios and overall
across all 8000 simulations. Stars next to Scenario 5 results indicate that this is the only scenario where the data
generating mechanism is actually a particular case of fractional polynomial on the log-odds scale and therefore performs
optimally. sABC is the scaled Area Between Curves as deﬁned in the proposals section, while maxdAE(d) indicates the
maximum absolute error for a single duration d ∈ (Dmin, Dmax) and coverage (%) is deﬁned as the percentage of the
true underlying curve included within the point-wise 95% conﬁdence region around the estimated curve.
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Figure 1. Prediction curves (red) of a random selection of 100 simulations against the true data generating curve (black)
for all the eight scenarios under the base-case conﬁguration. The base-case scenario assumes a sample size of 504 patients,
randomised to 7 equidistant arms, and ﬁts a fractional polynomial model to estimate the duration-response curve.
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(a) Comparison ﬂexible regression methods: 8000 simulations (b) Comparison ﬂexible regression methods: 95th percentiles
(c) Sensitivity to sample size: 8000 simulations (d) Sensitivity to sample size: 95th percentiles
Figure 2. Comparison of results of trial simulations from the eight scenarios varying either (i) the ﬂexible regression
method used (LS3, LS5, LSNE, MARS, FP), with total sample size of 504 patients (panels (a) and (b)), or (ii) the total
sample size between 250 and 1000 patients, using FP (panel (c) and (d)). Patients are divided in 7 equidistant duration
arms. The red horizontal line indicates 5% scaled Area Between Curves (sABC). In the left panels we show the boxplots
of the whole simulation results, while in the right panels we compare 95th percentiles from the eight scenarios. LS3-5:
Linear Spline with 3-5 knots. LSNE: Linear Spline with Non-Equidistant knots. MARS: Multivariable Adaptive Regression
Splines. FP: Fractional Polynomials.
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Figure 3. Prediction curves leading to the largest scaled Area Between Curves for each of the eight scenarios with the
base-case design, analysing data either with 3-knot linear spline (blue) or Fractional Polynomials (red).
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(a) Sensitivity to number of arms: 8000 simulations (b) Sensitivity to number of arms: 95th percentiles
(c) Sensitivity to placement of arms: 8000 simulations (d) Sensitivity to placement of arms: 95th percentiles
Figure 4. Comparison of results of trial simulations from the eight scenarios either varying the number of equidistant
arms (panels (a) and (b)) between 3 and 20, using Fractional Polynomials (FP), or using diﬀerent designs, Equidistant
(ED) or Not Equidistant (NED), comparing four diﬀerent regression methods (panels (c) and (d)). The total sample size
is always 504 patients. The red horizontal line indicates 5% scaled Area Between Curves. In the left panels we show the
boxplots of the whole simulation results, while in the right panels we compare 95th percentiles from the eight scenarios.
In panel (d), there is only one point for NED-LS3, since only in one scenario the 95th percentile for scaled Area Between
Curves was smaller than 0.25. LS3: Linear Spline with 3 knots. LSNE: Linear Spline with Non-Equidistant knots. MARS:
Multivariable Adaptive Regression Splines. FP: Fractional Polynomials.
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